Matteo Santoni

Matteo Santoni is an expert in Oncology at University of Macerata (Italy). As of October 2026, ScienceLeadR ranks Matteo Santoni in the top 1% of experts worldwide for Kidney Neoplasms, Urologic Neoplasms and Urogenital Neoplasms. Matteo Santoni has authored 592 publications, the most recent in 2026, and is an investigator in 3 clinical trials, 3 of them ongoing. SLR score: 2,002 (community average: 125). How the SLR is computed.

Oncology

Subspecialties: Urology - Immunology - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on October 25, 2026

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2011 - 2026

Source: PubMed

University of Macerata

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 592

Citations

Citations: 12 363 1st author: 100 Last author: 63 Unique author: 0

Main journals

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title	Journal	Year	Citations
Disitamab vedotin in urothelial carcinoma patients: a clinical trial perspective from ARON working group. PMID 42829986 — urinary bladder neoplasms, neoplasms, pharmacology, clinical, therapeutics	Expert Rev Clin Pharmacol	2026	0
Machine learning integrated explainable artificial intelligence in predicting toxicities of enfortumab vedotin in urothelial carcinoma: an exploratory study. PMID 42728857 — diabetes mellitus, intelligence, machine learning, neoplasm metastasis, therapeutics, diarrhea, learning, artificial intelligence	Expert Rev Anticancer Ther	2026	0
Sex-based analysis of first-line immune-based combinations in intermediate/poor-risk papillary, chromophobe, and unclassified renal cell carcinoma: an ARON-1 subanalysis. PMID 42718726 — cells, carcinoma, renal cell, liver, neoplasm metastasis, histology, sex, therapeutics	Front Oncol	2026	0
Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis. PMID 42667292 — intelligence, immunotherapy, machine learning, therapeutics, learning, biological therapy, artificial intelligence	Expert Opin Biol Ther	2026	0
Immune Checkpoint Inhibitor-Related Pneumonitis in Renal Cell Carcinoma: Clinical Features, Mechanisms, and Lessons from Lung Cancer. PMID 42650785 — cells, lung, neoplasms, carcinoma, renal cell, immunotherapy, immune checkpoint inhibitors, lung neoplasms	Biomolecules	2026	1

Clinical Studies 3

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 3

By status:

Recruiting 3

By type:

Observational 3

By Monocentric/Multicentric:

monocentric 3

multicentric2to4 0

multicentric5to9 0

multicentricup10 0

Main Topics

Male Urogenital Diseases 2

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study	Phase	Status	Start
ARON 3 Study International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa NCT06200558 — poly(adp-ribose) polymerase inhibitors, retrospective studies, neoplasms, prostate, passive cutaneous anaphylaxis, prostatic neoplasms, therapeutics	N/A	Recruiting	2024
International Multicentric Study ARON 1 NCT05287464 — cells, intelligence, bevacizumab, axitinib, carcinoma, renal cell, immunotherapy, nivolumab, ipilimumab, artificial intelligence, carcinoma	N/A	Recruiting	2022
ARON 2 Study Multicentric International Retrospective Study NCT05290038 — carcinoma, transitional cell, cells, intelligence, retrospective studies, drug therapy, immunotherapy, therapeutics, artificial intelligence, chemotherapy, carcinoma	N/A	Recruiting	2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS

Shopping Cart

System Maintenance Notice